Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial
Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of Cardiology’s 73rd Annual Scientific Congress in Atlanta, GA this week. The data was also released online, ahead of print, in a simultaneous manuscript in the...
April 11, 2024
Loading...
These were all messages
93933e22b6